SiRNA-HIF-1α delivered by attenuated Salmonella enhances the efficacy of Lenvatinib against hepatocellular carcinoma
P Chen, Y Wang, X Zhu, Y Huang, J Chen… - International …, 2024 - Elsevier
The treatment of hepatocellular carcinoma (HCC) remains a major challenge in the medical
field. Lenvatinib, a multi-target tyrosine kinase inhibitor, has demonstrated anti-HCC effects …
field. Lenvatinib, a multi-target tyrosine kinase inhibitor, has demonstrated anti-HCC effects …
Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy
R Xiao, Y Tian, J Zhang, N Li, M Qi, L Liu, J Wang… - Journal of …, 2024 - Elsevier
Background & Aims Natural killer (NK) cell-based anti-hepatocellular carcinoma (HCC)
therapy is an increasingly attractive approach that warrants further study. Siglec-9 interacts …
therapy is an increasingly attractive approach that warrants further study. Siglec-9 interacts …
SPINK1 Overexpression Correlates with Hepatocellular Carcinoma Treatment Resistance Revealed by Single Cell RNA-Sequencing and Spatial Transcriptomics
C Yang, L Guo, J Du, Q Zhang, L Zhang - Biomolecules, 2024 - mdpi.com
Low efficacy of treatments and chemoresistance are challenges in addressing refractory
hepatocellular carcinoma (HCC). SPINK1, an oncogenic protein, is frequently …
hepatocellular carcinoma (HCC). SPINK1, an oncogenic protein, is frequently …
Period2 is associated with immune cell infiltration and is a potential diagnostic and prognostic marker for hepatocellular carcinoma
X Chen, Q Zhao, H Wang, K Qiu, X Deng… - Frontiers in Molecular …, 2023 - frontiersin.org
Background: Hepatocellular carcinoma (HCC) health challenge worldwide. Many studies
showed that circadian rhythms play a critical role in tumor development. This study aimed to …
showed that circadian rhythms play a critical role in tumor development. This study aimed to …
Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 …
J Zhang, Y Yang, Z Wu, S Zhang, Z Lin, H Liu, J Hu… - BMJ open, 2024 - bmjopen.bmj.com
Introduction Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in
China. The combination of immune checkpoint inhibitors (ICIs) and antiangiogenic drugs …
China. The combination of immune checkpoint inhibitors (ICIs) and antiangiogenic drugs …
Bibliometric analysis of ferroptosis: a comprehensive evaluation of its contribution to cancer immunity and immunotherapy
Z Wang, H Zhang, L Wang, Z Ma, Y Cui, H Fu… - Frontiers in …, 2023 - frontiersin.org
Background In the past 5 years, ferroptosis-associated cancer immunity has been attracted
significant research interest. Objective This study was performed to identify and analyze the …
significant research interest. Objective This study was performed to identify and analyze the …
A novel prognostic model for predicting patient survival and immunotherapy responsiveness in hepatocellular carcinoma: insights into the involvement of T-cell …
S Tang, R Sun, K Tang, X Wei, M Liu… - Clinical and Translational …, 2024 - Springer
Background The cancer-associated biological mechanisms and the implementation of
immunotherapy are heavily impacted by the activities of T cells, consequently influencing the …
immunotherapy are heavily impacted by the activities of T cells, consequently influencing the …
[HTML][HTML] POSTN+ cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma
H Wang, Y Liang, Z Liu, R Zhang, J Chao… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Objective Hepatocellular carcinoma (HCC) poses a significant clinical challenge because
the long-term benefits of immune checkpoint blockade therapy are limited. A comprehensive …
the long-term benefits of immune checkpoint blockade therapy are limited. A comprehensive …
Investigation of folate-modified EGCG-loaded thermosensitive nanospheres inducing immunogenic cell death and damage-associated molecular patterns in …
L He, L Peng, L Wang, X Jiang, X Sun, H Li… - Biochemical and …, 2024 - Elsevier
Background The systemic treatment of advanced hepatocellular carcinoma is currently
facing a bottleneck. EGCG, the primary active compound in green tea, exhibits anti-tumor …
facing a bottleneck. EGCG, the primary active compound in green tea, exhibits anti-tumor …
Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives
J Liu, S Xia, B Zhang, DM Mohammed, X Yang, Y Zhu… - Discover Oncology, 2024 - Springer
Liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of
cancer death in the world, and hepatocellular carcinoma (HCC) is the most common form of …
cancer death in the world, and hepatocellular carcinoma (HCC) is the most common form of …